The Pharmaceutical Industry in Figures – Key Data 2021- EU

EFPIA and Vaccines Europe position on the European Health Emergency preparedness and Response Authority (HERA)

COVID-19 has shown that coordinated action at EU level is necessary to effectively respond to health emergencies. While during the pandemic the EU reacted to issues as they arose, the creation of HERA is a first step to putting Europe on the front foot in addressing global health threats. 

Please find here EFPIA and VE’s views and recommendations on a number of elements included in the Commission’s Decision establishing the Health Emergency Preparedness and Response Authority (HERA) and in the Proposal for a Council Regulation on a framework of measures for ensuring the supply of crisis-relevant medical countermeasures in the event of a public health emergency at Union level. 

EFPIA and VE, their national associations and member companies, look forward to working with HERA and all stakeholders towards the shared goal of a safer, healthier and more resilient Europe.

The COVID-19 pandemic is the public health challenge of our time. It demands a concerted effort and bold, new thinking to find solutions together. As the impact of COVID-19 continues to be felt across the world, the biopharmaceutical industry in Europe remains committed to working collaboratively across the research and healthcare communities, utilising our world-leading science, people and resources to tackle this outbreak.